 |
Tom Carey, M.D.University of Michigan Medical School, Otorhinolaryngology
Department
|
 |
Jeff JohnsonBS Chemistry Bemidji State University, Bemidji, Minnesota. PhD
Biochemistry North Dakota State University. Jeff joined Cayman Chemical as an Associate
Biochemist in 1992, and is now the Vice President of Biochemistry at Cayman Chemical
|
|
Stephen Kang, M.D.University of Michigan, General Surgery/ENT |
 |
Lawrence J. Marentette, M.D.University of Michigan, Professor, Department
of Neurosurgery, Director of Cranial Base Program. Clinical Interests: Head and neck surgery,
craniofacial surgery, cranial base disorders, skull base tumors, facial trauma, and facial
Plastic Surgery. Research Interests: Skull base tumor biology. The Cranial Base program
coordinates the treatment of vascular anomalies and facial trauma, and the resection of both
benign and malignant tumors involving the cranial base region. Our current research focuses on
skull base malignancies such as sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and
adenoid cystic carcinoma. We are currently following over 1,200 skull base patients for
continued investigation of treatment modalities and outcomes.
|
 |
Kirk MaxeyBS Organic Chemistry, Colorado State University. MD University of
Michigan. Kirk has been president and CEO of Cayman Chemical since 1980. Tasks: Website and
fundraising coordinator, science advisor
|
 |
Erin L. McKean, M.D.University of Michigan, Clinical Assistant Professor,
Department of Otolaryngology. Dr. McKean obtained her Medical Degree with Distinction in
Research Honors in 2003 at the University of Michigan. Dr. McKean completed her residency in
Otolaryngology – Head and Neck Surgery at the University of Michigan Medical Center and
subsequently completed a year-long fellowship in Cranial Base and Reconstructive surgery. Dr.
McKean holds appointments in Otolaryngology and Neurosurgery as a Clinical Assistant Professor.
She is the co-director of the endoscopic cranial base program.
|
 |
Scott Alan McLean, M.D., PhD.University of Michigan, Clinical Assistant
Professor, Department of Otolaryngology. Dr. McLean obtained a Bachelor of Science degree in
Cellular and Molecular Biology at the University of Michigan in Ann Arbor in 1991. In 1999, Dr.
McLean received his medical degree as well as his Ph.D. from the Medical College of Toledo Ohio.
He completed a four year residency in the Department of Otolaryngology at the Mayo Clinic in
2004 and a year Fellowship in the Cranial Base Program from 2004-2005 at the University of
Michigan Medical Center in Ann Arbor where he now is a full time clinician/surgeon faculty
member.
|
 |
Elizabeth MeadeBS Physiology and PhD Physiology, Michigan State University.
Beth studied COX-2 expression in breast cancer with Steve Prescott at the University of Utah
before joining Cayman in 1997, where she now works as the director of the immunoassay research
lab. Tasks: Mediator and growth factor measurements
|
 |
Stephen Edwin Sullivan, M.D.University of Michigan, Clinical Assistant
Professor, Department of Neurosurgery, Department of Otolaryngology and Department of Neurology.
He is the Director of Minimally Invasive Neurosurgery and Adult Hydrocephalus in the Department
of Neurosurgery, and co-director of the Minimally Invasive Skull Base Program based in the
Departments of Otolaryngology and Neurosurgery. He is co-surgeon along with Dr. William Chandler
in the University of Michigan Pituitary Cilnic. He holds joint appointments in the departments
of Neurosurgery, Otolaryngology and Neurology. Dr. Sullivan’s clinical interests include the use
of advanced endoscopic and computer navigational techniques in the treatment of brain,
pituitary, skullbase and spinal tumors. His research interests include the treament of
meningiomas and chordomas of the skull base and spine. His congenital neurosurgery practice
centers on the treatment of adult hydrocephalus, Chiari malformations and tethered cord
syndrome. He is a recognized specialist in the treatment of patients with von Hippel-Lindau
disease.
|
